BlossomHill Therapeutics, Inc. (BLSM) earnings
Quarterly results of BlossomHill Therapeutics, Inc. as filed with the SEC: revenue, net income and earnings per share for each of the last 2 quarters, the latest results release and when the next one is expected.
Latest quarter: Q2 FY2026
In Q2 FY2026 (ended June 30, 2026) BlossomHill Therapeutics, Inc. reported revenue of - and a net loss of $23.8M.
Diluted earnings per share were -$8.75.
The latest results release
BlossomHill Therapeutics reported its second quarter 2026 financial results and clinical pipeline updates.
Net loss for the second quarter of 2026 was $23.8 million, compared with $13.2 million for the same period in 2025.
Quarter by quarter
| Quarter | Revenue | vs year ago | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | - | - | -$23.8M | -$8.75 |
| Q2 FY2026 | - | - | -$13.2M | -$5.51 |
Results filings
- Quarterly report 10-Q
- Quarterly results 8-K
Get an email when BLSM reports
Follow BLSM and we email you its next results the day they are filed, with the numbers explained.